Clinical Data has signed a co-marketing deal with Roche Diagnostics for the installation of a 454 Genome Sequencer FLX System in one of its European facilities.
Subscribe to our email newsletter
Clinical Data said it plans to offer the 454 GS FLX ‘Next Generation’ sequencing technology as a fee-for-service offering to clients worldwide and has said it will collaborate with Roche to co-market the service.
“The Genome Sequencer FLX represents the most advanced state-of-the-art, high throughput and cost-effective sequencing technology to support the expectations and needs of our customers’ research,” stated Robert Bondaryk, senior vice president and general manager of Cogenics, a division of Clinical Data.
Financial terms of the deal were not disclosed.